Sign up to save your podcasts
Or
Share The Beacon
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Beacon
The Beacon episodes
- Are Tumor Mutation Burden and Nivolumab/Ipilimumab Ready for Clinical Use? Insights from CheckMate 227 (BMIC-035)
Dr. Jack West considers whether the results from the CheckMate 227 trial comparing nivolumab/ipilimumab to chemotherapy in patients with advanced NSCLC & high tumor mutation burden should change our management: AreTMB & nivo/ipi ready for prime time?
10 min - KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Negative (sub 1%) Tumor PD-L1 Expression (BMIC-033)
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and negative (
7 min - KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Low (1-49%) Tumor PD-L1 Expression (BMIC-032)
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and low (1-49%) tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of this patient subset.
7 min - KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and High (≥50%) Tumor PD-L1 Expression (BMIC-031)
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and high tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of these patients.
9 min - KEYNOTE-189: Key Summary of a Practice-Changing Trial in Advanced Non-Squamous NSCLC (BMIC-030)
Dr. Jack West reviews the trial design, efficacy endpoints, and toxicity results of the KEYNOTE-189 trial of pembrolizumab or placebo added to cisplatin or carboplatin with pemetrexed chemo in advanced non-squamous NSCLC with any PD-L1 expression.
14 min - Is Chemotherapy More Effective After Prior Immunotherapy? (BMIC-029)
Dr. Jack West presents early data suggesting that chemotherapy may be more effective after prior immunotherapy than otherwise.
6 min - New Insights on Acquired Resistance to Immune Checkpoint Inhibitors for NSCLC: Implications for Treatment Options (BMIC-028)
Dr. Jack West reviews new data on patterns of acquired resistance after a response to immune checkpoint inhibitors for advanced NSCLC, along with the clinical implications of various options based on these observations.
12 min - Is immunotherapy ineffective in patients with driver mutation-positive advanced NSCLC? Time to walk that back. (BMIC-027)
Dr. Jack West summarizes the evolving data shaping our understanding of the role of immune checkpoint inhibitors for patients with EGFR- or ALK-positive advanced NSCLC, including more recent data that should change our perspective.
11 min - Chemo/Immunotherapy in Advanced Squamous NSCLC: What is the Impact of IMpower131? (BMIC-026)
Dr. Jack West reviews the preliminary positive result form the IMpower131 trial of chemo +/- atezolizumab immunotherapy and considers what the clinical significance of these findings should be for patients with advanced squamous NSCLC.
10 min - Is Durvalumab (Imfinzi) in Stage III NSCLC Curing Patients or Just Treating Metastatic Disease Earlier? Importance of Overall Survival and Implications for Duration of Treatment (BMIC-025)
Dr. Jack West explores the importance of following the overall survival of patients on the PACIFIC trial and considers still open questions of whether consolidation durvalumab (Imfinzi) in stage III unresectable NSCLC should be discontinued after a year.
7 min
About The Beacon
From the publisher's feed
Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.